• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于精确肿瘤细胞重编程和增强肿瘤治疗的仿生基因编辑系统。

Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy.

作者信息

Qiao Lei, Gao Min, Yi Xiaoqing, Peng Hui, Zhang Ruijie, Yao Wanqing, Sun Gengyun, He Xiaoyan

机构信息

Department of Polymer Science and Engineering, University of Science and Technology of China, Hefei 230026, China.

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.

出版信息

J Control Release. 2023 Apr;356:663-677. doi: 10.1016/j.jconrel.2023.03.020. Epub 2023 Mar 22.

DOI:10.1016/j.jconrel.2023.03.020
PMID:36924897
Abstract

The abnormal level of hypoxia-inducible factor-1 alpha (HIF-1α) is closely related to cancer metastasis and treatment resistance. CRISPR-Cas9-based gene editing technology has sparked profound hope to solve this issue by precise gene disruption, although the in vivo application remains hindered by the lack of a safe and efficient delivery strategy. Herein, we developed a cell membrane biomimetic core-shell system for light-controllable, precise gene editing. The inner core of the system comprises protamine for CRISPR-Cas9/sgRNA plasmid (pCas9) loading and calcium ions for efficient pCas9 transfection. The shell of the system is camouflaged by a cell membrane and modified with AS1411 aptamers for tumor targeting and photosensitizers to induce lysosomal escape and pCas9 release through reactive oxygen species production, thereby producing light-controllable enhanced gene editing. Neoplastic H1299 cells were reprogrammed using the biomimetic gene editing system upon laser irradiation with reduced VEGF and Vimentin expression, leading to enhanced antimetastatic effects. Genetic disruption of HIF-1α augmented the in vivo chemotherapeutic efficacy of paclitaxel. Our approach of using a membrane-camouflaged system combined with light augmentation provides a potential solution for the in vivo delivery of CRISPR-Cas9 as well as a feasible strategy for cancer therapy.

摘要

缺氧诱导因子-1α(HIF-1α)水平异常与癌症转移及治疗耐药密切相关。基于CRISPR-Cas9的基因编辑技术通过精确的基因破坏有望解决这一问题,尽管其体内应用仍因缺乏安全有效的递送策略而受阻。在此,我们开发了一种用于光控、精确基因编辑的细胞膜仿生核壳系统。该系统的内核包含用于加载CRISPR-Cas9/sgRNA质粒(pCas9)的鱼精蛋白和用于高效pCas9转染的钙离子。系统的外壳由细胞膜伪装,并修饰有用于肿瘤靶向的AS1411适配体和用于通过产生活性氧诱导溶酶体逃逸和pCas9释放的光敏剂,从而产生光控增强基因编辑。在用仿生基因编辑系统对肿瘤性H1299细胞进行激光照射后,其VEGF和波形蛋白表达降低,导致抗转移作用增强。对HIF-1α进行基因破坏增强了紫杉醇的体内化疗效果。我们使用膜伪装系统结合光增强的方法为CRISPR-Cas9的体内递送提供了一种潜在解决方案,同时也为癌症治疗提供了一种可行策略。

相似文献

1
Biomimetic gene editing system for precise tumor cell reprogramming and augmented tumor therapy.用于精确肿瘤细胞重编程和增强肿瘤治疗的仿生基因编辑系统。
J Control Release. 2023 Apr;356:663-677. doi: 10.1016/j.jconrel.2023.03.020. Epub 2023 Mar 22.
2
Polymeric micellar nanoparticles for effective CRISPR/Cas9 genome editing in cancer.聚合物胶束纳米粒用于癌症中有效的 CRISPR/Cas9 基因组编辑。
Biomaterials. 2024 Sep;309:122573. doi: 10.1016/j.biomaterials.2024.122573. Epub 2024 Apr 17.
3
Biomimetic Mineralized CRISPR/Cas RNA Nanoparticles for Efficient Tumor-Specific Multiplex Gene Editing.仿生矿化 CRISPR/Cas RNA 纳米颗粒用于高效肿瘤特异性多重基因编辑。
ACS Nano. 2023 Aug 8;17(15):15025-15043. doi: 10.1021/acsnano.3c04116. Epub 2023 Jul 23.
4
A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.一种多功能非病毒载体,用于递送 MTH1 靶向的 CRISPR/Cas9 系统,用于非小细胞肺癌治疗。
Acta Biomater. 2022 Nov;153:481-493. doi: 10.1016/j.actbio.2022.09.046. Epub 2022 Sep 24.
5
Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.肽和适体修饰的递药系统,用于靶向递送 Cas9/sgRNA 质粒以介导抗肿瘤基因组编辑。
ACS Appl Mater Interfaces. 2019 Jul 10;11(27):23870-23879. doi: 10.1021/acsami.9b05772. Epub 2019 Jul 1.
6
Knockdown of hypoxia-inducible factor-1 alpha by tumor targeted delivery of CRISPR/Cas9 system suppressed the metastasis of pancreatic cancer.肿瘤靶向递送 CRISPR/Cas9 系统敲低低氧诱导因子-1α 抑制胰腺癌转移。
J Control Release. 2019 Jun 28;304:204-215. doi: 10.1016/j.jconrel.2019.05.019. Epub 2019 May 14.
7
Biomimetic Mineralization-Based CRISPR/Cas9 Ribonucleoprotein Nanoparticles for Gene Editing.基于仿生矿化的 CRISPR/Cas9 核糖核蛋白纳米颗粒用于基因编辑。
ACS Appl Mater Interfaces. 2019 Dec 26;11(51):47762-47770. doi: 10.1021/acsami.9b17598. Epub 2019 Dec 10.
8
Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.CRISPR/Cas9 介导的基因组编辑和肿瘤细胞内靶向的最新进展:癌症管理的创新策略。
Cancer Commun (Lond). 2022 Dec;42(12):1257-1287. doi: 10.1002/cac2.12366. Epub 2022 Oct 9.
9
Co-delivery of Sorafenib and CRISPR/Cas9 Based on Targeted Core-Shell Hollow Mesoporous Organosilica Nanoparticles for Synergistic HCC Therapy.基于靶向核壳结构中空介孔有机硅纳米粒子的索拉非尼和 CRISPR/Cas9 共递送用于协同 HCC 治疗。
ACS Appl Mater Interfaces. 2020 Dec 23;12(51):57362-57372. doi: 10.1021/acsami.0c17660. Epub 2020 Dec 10.
10
Phenylboronic acid-functionalized polyaminoglycoside as an effective CRISPR/Cas9 delivery system.苯硼酸功能化聚氨基糖苷作为一种有效的 CRISPR/Cas9 递送系统。
Biomater Sci. 2021 Oct 26;9(21):7104-7114. doi: 10.1039/d1bm00185j.

引用本文的文献

1
Advancements in CRISPR/Cas systems for disease treatment.用于疾病治疗的CRISPR/Cas系统的进展。
Acta Pharm Sin B. 2025 Jun;15(6):2818-2844. doi: 10.1016/j.apsb.2025.05.007. Epub 2025 May 17.
2
Precisely Targeted Nanoparticles for CRISPR-Cas9 Delivery in Clinical Applications.用于临床应用中CRISPR-Cas9递送的精准靶向纳米颗粒
Nanomaterials (Basel). 2025 Apr 2;15(7):540. doi: 10.3390/nano15070540.
3
Natural Biopolymer-Based Delivery of CRISPR/Cas9 for Cancer Treatment.基于天然生物聚合物的CRISPR/Cas9递送用于癌症治疗
Pharmaceutics. 2023 Dec 30;16(1):62. doi: 10.3390/pharmaceutics16010062.
4
Cell Membrane-Camouflaged Nanoparticles Mediated Nucleic Acids Delivery.细胞膜伪装纳米颗粒介导的核酸递送。
Int J Nanomedicine. 2023 Dec 28;18:8001-8021. doi: 10.2147/IJN.S433737. eCollection 2023.